This paper presents findings from a preliminary review of the status of training and certification in computing in construction. A review of the academic literature, market trends, and a questionnaire-based survey validate the demand for training and certification in computing in construction. The findings reveal the need for a detailed articulation of areas within computing and construction that require training and certification. There is an expectation that academia and professional associations will lead training and certification to ensure quality. There is a need to train and certify trainers to ensure quality and build capacity to decentralize the training and certification ecosystem.

Chrysin is a flavonoid possessing potential pharmacological activities against many diseases including cancer. Many studies have been reported on Chrysin showing anticancer activity against colon cancer. However, the mechanism with which Chrysin shows its anticancer activity is not known yet. Hence, the current study was framed to understand the molecular mechanism of Chrysin against colon cancer via gene set enrichment and network pharmacology analysis coupled with molecular docking study. Initially, Chrysin probable targets were identified by SwissTargetPrediction and their molecular pathway enrichment was analyzed by the STRING and KEGG pathway databases. The network among Chrysin, probable protein targets, and its pathways were constructed with the aid of Cytoscape 3.6.1v. Molecular docking was carried out with the aid of AutoDock Vina by PyRx 0.8v. Molecular dynamics was carried out by Schrodinger Desmond v6.1 software. Druggability, side effects, and ADMET analysis were determined using MolSoft, ADVERPred, and admetSAR2.0 web server, respectively. Chrysin potentially acts via metabolic pathways and Ras and PI3K-Akt signaling pathways associated with the progression of cancer. Among the probable targets, Chrysin exhibited the highest binding affinity against epidermal growth factor receptor comparable to standard molecule Erlotinib, and its root mean square deviation and interactions were found stable at 20 ns MD production run. Both Chrysin and Erlotinib shared common interactions with Asp831 active site residue and confirmed their potential antagonistic effect. In conclusion, Chrysin may serve as a potential anticancer small molecule in the future for the management and treatment of colon cancer.

Cancer is a disease characterized by the uncontrolled multiplication of cells in human body with the inability to be controlled or stopped, consequently forming tumors of malignant cells with the potential to be metastatic. Around one third of deaths due to cancer are due to five leading behavioral and dietary risks: high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use and alcohol use. According to the World Health Organization, cancer is the second leading cause of death globally and about one in 6 deaths is due to cancer. The economic impact of cancer is significant and is increasing. The total annual economic cost of cancer in 2010 was estimated at approximately US 1.16 trillion. The economic burden on low-and middle-income countries is profound since approximately 70% of deaths due to cancer occur in these countries. To combat the growing challenge, development in cures and preventative therapies has emerged through rapid research in this area. Current treatments include chemotherapy, radiotherapy and chemically derived drugs which have severe side effects. Therefore, there is an increasing impetus on development and use of natural alternative therapies against cancer. Plants sources have been exploited in medicine for their natural antiseptic properties. Thus, research has developed into investigating the potential properties and uses of terrestrial plant extracts for the preparation of potential nanomaterial-based drugs for diseases including cancer. This article aims to take an overview of naturally derived compounds that have anticancer therapeutic properties and their current status in this field.

No abstract

No abstract